BPC-157

What is BPC-157?

BPC-157 is a synthetic peptide of fifteen amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its formula is C62H98N16O22, molecular weight 1419.5 g/mol, CAS number 137525-51-0. BPC stands for body protection compound, the name given to the gastric-juice protein from which the fragment was identified. The fragment was isolated because, unlike most peptides, it is unusually resistant to degradation in gastric fluid.

It is manufactured by solid-phase peptide synthesis, the standard route for research peptides, rather than extracted from tissue. Peptides of this kind are typically characterised by HPLC for purity and by mass spectrometry or a reference standard for identity. The published WOLVERINE certificate (batch C26071, a third-party HPLC report from Analiza Białek on a sample Celyfe supplied) reports 99% purity for each peptide and a measured content of about 91% of label for BPC-157 and 85% for TB-500; it does not include mass spectrometry. The guide What are research peptides? explains the synthesis and testing in more detail.

How BPC-157 is used in the Celyfe system

Celyfe supplies BPC-157 only in combination, never as a single-compound pen. It is present at 15mg per pre-filled 3ml cartridge in three formulations that build on each other. Each pen ships pre-mixed and dispenses 0.01ml per click across 300 clicks. The published WOLVERINE certificate (batch C26071, a third-party HPLC report from Analiza Białek on a sample Celyfe supplied) reports 99% purity for each peptide and a measured content of about 91% of label for BPC-157 and 85% for TB-500; it does not include mass spectrometry. Certificates for the GLOW and KLOW pens are being re-issued and are not yet published, so no GLOW or KLOW test result is claimed here.

• WOLVERINE Pen: BPC-157 15mg and TB-500 15mg, 30mg in total, 0.100mg per click. The two-peptide base and the control arm for GLOW and KLOW study designs.
• GLOW Pen: the same two plus GHK-Cu 75mg, 105mg in total, 0.350mg per click.
• KLOW Pen: the GLOW set plus KPV 15mg, 120mg in total, 0.400mg per click.

What the research literature covers

The sources below include a 2025 literature and patent review of BPC-157 (Jozwiak et al., Pharmaceuticals) and a 2025 Arthroscopy editorial commentary, Injectable Therapeutic Peptides - An Adjunct to Regenerative Medicine and Sports Performance?, which is an opinion piece rather than a study. The guide What is BPC-157? describes the published work as cell-culture and animal-model studies of signalling pathways including angiogenesis and growth-factor signalling such as VEGF.

That literature is preclinical. It describes what has been observed under laboratory conditions and does not establish an effect in humans. BPC-157 is not an approved medicine anywhere, and every Celyfe pen is supplied and labelled for in-vitro research use only.

Handling, storage and quality

All three BPC-157 pens are pre-mixed solutions, so they are refrigerated at 2 to 8 degrees Celsius and never frozen. Freeze-thaw cycling damages peptides already in solution. Keep the cartridge sealed and protected from light, prime the pen before first use and use aseptic technique. Because there is no reconstitution step, no bacteriostatic water is needed, which removes the handling errors described in the bacteriostatic water guide.

A batch-specific certificate for a combination pen should report separate identity and purity results for each peptide rather than a single blended figure. The COA guide sets out what to look for on the document.

Legal position in the UK

Research peptides such as BPC-157 are not controlled drugs in the UK and can be bought and possessed for laboratory research. What UK law regulates, through the Human Medicines Regulations 2012 and the MHRA, is selling or marketing a substance as a medicine for human use. Celyfe supplies BPC-157 strictly for research and makes no therapeutic claim. The guide Are peptides legal in the UK? is general information, not legal advice.

Related compounds and comparisons

BPC-157 vs TB-500 is the comparison most readers arrive for. The two come from different origins and are studied through different mechanisms, BPC-157 in relation to angiogenesis and growth-factor signalling, TB-500 through actin binding, and they are formulated as a pair in the WOLVERINE Pen. GHK-Cu vs BPC-157 explains why the copper tripeptide is added on top in the GLOW and KLOW pens rather than offered as an alternative.

BPC-157 vs Thymosin Alpha-1 sets it against the immune-modulating peptide in the compound library. Thymosin Alpha-1 is not in any Celyfe pen. For choosing between the pens themselves, see WOLVERINE Pen vs GLOW Pen and GLOW Pen vs KLOW Pen.